COLL
HEALTHCARECollegium Pharmaceutical Inc
AI Insight
What's Moving COLL Today?
No stock-specific AI insight has been generated for COLL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.19$50.79
$34.62
Fundamentals
Market Cap$1.1B
P/E Ratio16.7
EPS$2.06
Dividend Yield—
Dividend / Share—
ROE27.4%
Profit Margin9.4%
Debt / Equity—
Trading
Volume318K
Avg Volume (10D)—
Shares Outstanding32.4M
COLL News
33 articles- Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?Yahoo Finance·Jun 23, 2026
- Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?Simply Wall Street·Jun 21, 2026
- 3 of Wall Street’s Favorite Stocks We Approach with CautionYahoo Finance·Jun 19, 2026
- Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 5, 2026
- 2 Reasons to Sell COLL and 1 Stock to Buy InsteadYahoo Finance·Jun 3, 2026
- Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price WeaknessYahoo Finance·Jun 2, 2026
- Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD PortfolioYahoo Finance·May 27, 2026
- Collegium to Participate in 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- 3 Growth Stocks We’re Skeptical OfYahoo Finance·May 26, 2026
- Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity awardStock Titan·May 19, 2026
- Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)Stock Titan·May 19, 2026
- Collegium (COLL) director sells shares, exercises options and receives RSU grantStock Titan·May 19, 2026
- Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3Stock Titan·May 19, 2026
- Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grantStock Titan·May 19, 2026
- Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst QuestionsYahoo Finance·May 18, 2026
- Have Collegium Pharmaceutical Insiders Been Selling Stock?Simply Wall Street·May 17, 2026
- Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To KnowYahoo Finance·May 17, 2026
- [SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment DisclosureStock Titan·May 16, 2026
- [144] COLLEGIUM PHARMACEUTICAL, INC SEC FilingStock Titan·May 16, 2026
- Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong FactorsYahoo Finance·May 14, 2026
- 1 Healthcare Stock with Competitive Advantages and 2 We Brush OffYahoo Finance·May 13, 2026
- [SCHEDULE 13G] COLLEGIUM PHARMACEUTICAL, INC Passive Investment Disclosure (>5%)Stock Titan·May 13, 2026
- Collegium Pharmaceutical Completes AZSTARYS ADHD Business AcquisitionTipRanks·May 12, 2026
- Collegium Completes Acquisition of AZSTARYS® from Corium TherapeuticsYahoo Finance·May 12, 2026
- COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive ResultsYahoo Finance·May 11, 2026
- A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is ProposedSimply Wall Street·May 11, 2026
- Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Collegium (COLL) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Collegium Pharmaceutical Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 7, 2026
- Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·May 7, 2026
- Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock SoarsYahoo Finance·May 7, 2026
- Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHDThe Motley Fool·Mar 31, 2026
All 33 articles loaded
Price Data
Open$33.92
Previous Close$33.45
Day High$34.87
Day Low$33.79
52 Week High$50.79
52 Week Low$29.19
52-Week Range
$29.19$50.79
$34.62
Fundamentals
Market Cap$1.1B
P/E Ratio16.7
EPS$2.06
Dividend Yield—
Dividend / Share—
ROE27.4%
Profit Margin9.4%
Debt / Equity—
Trading
Volume318K
Avg Volume (10D)—
Shares Outstanding32.4M
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—